Results for tag: "Blincyto"

Blincyto is an oncology drug used to treat certain types of acute lymphoblastic leukemia (ALL). It is a chimeric antigen receptor (CAR) T-cell therapy, which is a type of immunotherapy that uses a patient's own immune cells to fight cancer. Blincyto works by targeting a protein called CD19, which is found on the surface of leukemia cells. The drug is administered intravenously and works by stimulating the patient's immune system to attack and destroy the cancer cells. Blincyto has been approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory B-cell precursor ALL in adults and children. The Blincyto market is a rapidly growing segment of the oncology drug market. It is estimated that the global Blincyto market will reach $1.5 billion by 2027. The market is driven by the increasing prevalence of ALL, the growing demand for immunotherapies, and the increasing availability of Blincyto in the market. Some of the major companies in the Blincyto market include Amgen, Novartis, Gilead Sciences, Celgene, and Kite Pharma. Show Less Read more